The PennZone

  • Home
  • Entertainment
  • Marketing
  • Music
  • Non-profit
  • Books
  • Education
  • Automotive
  • Sports

ExpressCells Named Most Fundable Company by Pepperdine Graziadio Business School
The PennZone/10088820

Trending...
  • Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
  • Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd
  • Boyertown Mechanic Travels to Nashville to Learn How AI Is Changing Auto Repair
PHILADELPHIA - PennZone -- ExpressCells, Inc., a biotechnology company that creates advanced cell lines for research, was awarded a silver designation on the Pepperdine Graziadio Business School's third annual Most Fundable Companies® List. ExpressCells competed against over 4,500 early-stage U.S. startups spanning all 50 states, all with less than $10 million in annual revenue, to be named among a list of twenty. The Most Fundable Companies initiative is designed to recognize exceptional entrepreneurs who are solving today's problems with inventive solutions and are also seeking investment capital to fuel their company's growth.

"Since starting ExpressCells in 2018, we've been focused on helping biological researchers conduct better experiments.. The Most Fundable Companies initiative provided us with a data-driven analysis that we have already incorporated into our fundraising activities," said Matt Handel, CEO. "It's validating that Pepperdine Graziadio Business School recognizes entrepreneurs throughout the country and provides resources to assist startups in securing private capital to accelerate meaningful innovation across industries and communities."

More on The PennZone
  • The Alistair Apartments Reaches 95% Occupancy in Downtown Lancaster, PA
  • Food Journal Magazine Focuses Its Los Angeles Dining Coverage Across Three Editorial Verticals
  • Where Do Missouri Plane Crashes Really Happen? Not Where You'd Think
  • LCC Asia Pacific Sponsors CubeSatPlus 2026 at UNSW Sydney
  • Kellyn Endorses National Push to Expand Food is Medicine

The Most Fundable Companies initiative involved a multi-phase assessment that evaluated several company variables, including financial projections, market opportunity, intellectual property, and the strength of the management team, all of which were used to produce a fundability score. The Most Fundable Companies were evaluated and selected based on their readiness for private investment. Most Fundable Companies is powered by The Venture Alliance.

As a winner on the Most Fundable Companies List, ExpressCells will be profiled on Entrepreneur.com and be featured in the December print issue of the magazine. For a complete list of the winners, visit www.pepperdine.edu/mfc-list, where you can vote for ExpressCells as the "crowd favorite" through November 1.

The Pepperdine Most Fundable Companies list does not represent an offer to sell securities. It neither constitutes investment advice, nor is an endorsement of any particular product or service. Pepperdine University is not a broker-dealer and does not perform services provided by a broker-dealer, including but not limited to any financial or investment advising.

More on The PennZone
  • LATO AI Automates Customer Communication to Help CSide Sports Academy and BAT 24 Nation Grow
  • Real Estate Syndication Attorney Tilden Moschetti Releases The Real Estate Private Equity Blueprint
  • 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate
  • Tina Hasselbusch, Turnstone Creative Co-founder and Chief Executive Officer, Named to LVB 300
  • Pittsburgh Family Law Attorneys at Pollock Begg Earn Top Honors in 2027 Best Lawyers Guide

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its uses it proprietary genome editing technology, in combination with CRISPR/Cas9, to create advanced, knock-in cell lines to enhance drug discovery and other biological research. It shortens the time for delivery of knock-in cell lines by up to 75% relative to current technologies. The speed of the process allows ExpressCells to insert one to three genes into the same cell line. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines.

ExpressCells' genetic engineering technology was invented at the Temple University School of Pharmacy by Oscar Perez-Leal, MD. ExpressCells holds a global, exclusive license on this technology. For more information, visit xpresscells.com (http://www.xpresscells.com/).

Contact
Matt Handel
***@xpresscells.com


Source: ExpressCells

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention
  • San Diego Attorney Anthony Z. Vargas Narrows Practice to Employment Law, Representing Employees Only
  • Solid Earth Introduces RealtyID, a Universal Identity Spine for the Real Estate Industry
  • GGILabs Expands Local SEO Services to Help Businesses Compete in AI-Driven Search
  • Sara Viteri, Turnstone Creative Senior Producer, Named to Lehigh Valley Business' Forty Under 40
  • Boyertown Mechanic Travels to Nashville to Learn How AI Is Changing Auto Repair
  • Colonial Nissan Earns Capital One Top Performing Dealership Award
  • BlazeHive's AI SEO Agent Outranks Human Writers on 500+ Google Top-3 Results in 5 Months, on Autopilot
  • Logistics Expert Asks A Question Biology Has Overlooked: How Evolution Assembles Coordinated Novelty
  • Phinge Exposes Massive AI Security Risks, Claiming Its Patented Hardware-Verified Architecture Is The Only Safeguard Against Surveillance Capitalism
  • Phinge & CEO Robert DeMaio Publicly Declare Cash Settlements or Judgments Alone Cannot & Will Not Remedy the Deep Public Harm of Infringing Its IP
  • Dana Flanagan Expands the Authority Architect, Bringing a Nontraditional Approach to Executive Authority, Strategic Access and Business Growth
  • Phinge's Netverse: Reclaiming the Digital Frontier For Everyone Through CEO Robert DeMaio's Vision of a True App-less, User Data Sovereign World
  • DuraFast Label Company Launches Seiko SLP850 2" Thermal Printer with Free Label Promotion
  • Scientific Figure Releases Free Layout Template Libraries for Graphical Abstracts and Research Posters
  • Permian Museum announces the addition of an Ancient Alien Artifacts photo gallery
  • Philly Tailgates Announces Full 2026 Eagles Season Schedule, Opening With Back-to-back Events
  • The Golden Jazz Fest Shuttle Returns for 2026
  • KeysCaribbean Resorts Offer Savings On Vacations Through Aug. 31, Preview Exceptional Select Fall Rates of Less Than $200/Night
  • Fit Body Boot Camp Launches Nationwide 'Fit Body Forever' Workshops to Help Adults 60+ Rebuild Strength and Prevent Falls

Popular on PennZone

  • Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community - 587
  • Omnitronics launches Ecosystem Health Dashboard to enable proactive monitoring across dispatch environments - 107
  • Leeds Billboard Campaign Drives 188% Traffic Uplift as AI Enquiries Rise 266% for Loud! OOH - 101
  • Sister Files Lawsuit Against Georgia Funeral Home for Alleged Mishandling of Brother's Remains
  • Bethany Nikitenko Appointed to Philadelphia Trial Lawyers Association Board of Directors
  • AI, Drones, Defense & Explosive Growth: Why ZenaTech Is Emerging as One of the Most Compelling Technology Growth Stories (N A S D A Q: ZENA)
  • $40 Billion Global Market Value by 2030 Projected in Unmanned Aerial Vehicle or Other Drone Technology Sector, Growing at 9.2% Compound Annual Growth
  • Boston Industrial Solutions, Inc. Introduces SAP-G70 Primer for bonding silicone to silicone and other materials
  • Salestrics Releases Version 2.0 to Unify CRM, Business Email, and Operations on a Single Customer Graph
  • Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare

Similar on PennZone

  • FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention
  • synseer Nominated for Best Startup in 2026 Prix Galien USA Awards Following Record Breaking Applicant Pool
  • FDA Clears Major Regulatory Hurdle as Preservative-Free Ketamine Program Moves Within Reach of Commercialization: NRx Pharmaceuticals: (NAS DAQ: NRXP)
  • Boston Industrial Solutions, Inc. Introduces SAP-G70 Primer for bonding silicone to silicone and other materials
  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
  • Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
  • Roohid Parast, J&J Scientist, Comments on New Psoriasis Biomarker Study
  • Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
  • From DECA Finalist to Translational Scientist: Roohid Parast on Business Training in Biopharma
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us